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Summary
A high prevalence of vitamin D insufficiency and deficiency exists world-
wide, which is associated with an increased incidence and severity of a
range of immune-mediated diseases. This has resulted in considerable
interest in the immunodulatory functions of vitamin D. The active form
of vitamin D, 1a,25-dihydroxyvitamin D3 [1,25(OH)2D3], has been shown
to increase the frequency of Foxp3+ CD4+ T regulatory (Treg) cells when
present at high concentrations or under strong T-cell stimulation in cul-
ture. Supporting evidence exists in vivo for a positive association between
serum 25(OH)D and Foxp3+ Treg cell numbers in humans. The aim of
this work was to identify the cytokine milieu required in vitro to promote
Foxp3+ Treg cells in cultures containing 1,25(OH)2D3 at more moderate
concentrations (107 M). Stimulation of human CD4+ T cells with a com-
bination of 1,25(OH)2D3 and transforming growth factor-b (TGF-b)
greatly increased the frequency of Foxp3+ Treg cells, which is proposed to
result from the preferential expansion of Foxp3+ Treg cells, as compared
with the Foxp3 effector T cells, in culture. The differential effect on pro-
liferation may result from enhanced availability and usage of interleukin-2
by the Foxp3+ Treg cells compared with Foxp3 effector T cells. In sum-
mary, modulation of the cytokine environment to one high in TGF-b in
the presence of 1,25(OH)2D3 (10
7
M) significantly increased Foxp3+ Treg
cell frequency. These data provide additional evidence for the important
immunomodulatory properties of 1,25(OH)2D3 that exist and may help
to control inflammatory diseases.
Keywords: 1a,25-dihydroxyvitamin D3; Foxp3+ regulatory T cells; inter-
leukin-2; transforming growth factor-b.
Introduction
A high prevalence of vitamin D insufficiency has been
widely linked with a number of immune-mediated dis-
eases including autoimmune conditions and asthma.1
This association is believed to be due, in part, to the
numerous immunomodulatory properties of the active
form of vitamin D, 1a,25-dihydroxyvitamin D3 [1,25
(OH)2D3]. 1,25(OH)2D3 has been reported to inhibit
proliferation of effector cells and inflammatory cytokines
while enhancing production of anti-inflammatory cyto-
kines such as interleukin-10 (IL-10) and to increase regu-
latory T (Treg) cell populations.2,3
Evidence that 1,25(OH)2D3 may be important in the
induction and maintenance of Foxp3+ Treg cells in vivo
derives from data showing that serum concentrations of
25-hydroxyvitamin D [25(OH)D] positively correlates
with the number and frequency of Foxp3+ Treg cells in
the peripheral blood as well as with the frequency
of Foxp3+ Treg cells in bronchoalveolar lavage fluid of
Abbreviations: 1a,25-dihydroxyvitamin D3, 1,25(OH)2D3; 25-hydroxyvitamin D, 25(OH)D; IL-10, interleukin-10; STAT5, signal
transducer and activator of transcription 5; TGF-b, transforming growth factor-b; Treg, regulatory T
ª 2014 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 143, 52–6052
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
IMMUNOLOGY OR IG INAL ART ICLE
paediatric asthma patients.4–7 This is supported by reports
using animal models and also by in vitro studies with
human peripheral blood T cells.8–10 We have previously
reported that 1,25(OH)2D3 increases the frequency of
Foxp3+ Treg cells as well as IL-10+ Treg cells in vitro,
although little or no co-expression of these molecules was
observed in culture.5,11 However, only high doses of vita-
min D, in the order of 106 M 1,25(OH)2D3, and rela-
tively long culture periods of 2 weeks, led to the
reproducible increase in the frequency of Foxp3+ Treg
cells, with lower concentrations of 1,25(OH)2D3 (10
7–
108 M) more likely to increase IL-10+ Treg cells.5
The cytokine milieu undoubtedly plays an important
role in Foxp3+ Treg cell generation. For example, in our
1,25(OH)2D3 culture system the frequency of Foxp3
+
Treg cells was reduced by the addition of IL-10 into the
culture but was increased by anti-IL-10 receptor antibody.
Transforming growth factor-b (TGF-b) has been widely
implicated in the generation of Foxp3+ Treg cells from
naive CD4+ T cells.12–14 Additionally TGF-b in combina-
tion with the vitamin A metabolite, retinoic acid, is capa-
ble of converting effector cells into Foxp3+ Treg cells with
gut homing properties, facilitated by mucosal CD103+
dendritic cells.15–20 To maintain stable Foxp3 expression,
TGF-b is required to bind to a conserved non-coding
sequence region upstream of the Foxp3 gene.21
Another cytokine important for the survival, mainte-
nance and proliferation of Foxp3+ Treg cells is IL-2.22
Although IL-2 was originally described as a T-cell growth
factor, IL-2 knockout mice were shown to develop a
lethal lymphoproliferative disease as a result of the lack of
Treg cells.23–25 Foxp3+ Treg cells express high levels of
CD25, the high-affinity subunit of the IL-2 receptor, and
high levels of IL-2 are required for expansion of Foxp3+
Treg cells in culture.26–30 Additionally it has been shown
that IL-2 inhibits the generation of T helper type 17 cells
as well as the production of IL-17A, which are known to
be inhibitory to Foxp3+ Treg cell development.31 The
immunomodulatory properties of IL-2 have led to it
being proposed to have therapeutic potential in diseases
such as graft-versus-host disease.32 Interestingly, although
Foxp3+ Treg cells are dependent upon IL-2, they appear
incapable of producing IL-2 themselves and are depen-
dent on IL-2 production from effector T cells.33
The aim of this work was to identify which cytokine
environment was necessary to increase the frequency of
Foxp3+ Treg cells in the presence of lower, putatively
more physiological concentrations of 1,25(OH)2D3. We
hypothesized that lower concentrations of 1,25(OH)2D3
in an environment high in TGF-b would increase the fre-
quency of Foxp3+ Treg cells. To understand the mecha-
nisms behind this, the impact of TGF-b on the
proliferation, CD25 expression, IL-2 synthesis and signal
transducer and activator of transcription 5 (STAT5)
phosphorylation of CD4+ Foxp3+ and CD4+ Foxp3
populations was compared. The data suggest that prefer-
ential survival and expansion of Foxp3+ Treg cells occurs
through enhanced CD25 expression and greater IL-2 con-
sumption, as determined by phosphorylation of STAT5.
Materials and methods
Cell isolation and culture
Peripheral blood was obtained from healthy donors after
receiving the approval of the Guy’s Hospital Ethics
Committee (09/H0804/77) and full written informed con-
sent from all subjects. CD4+ T cells were purified from
peripheral blood mononuclear cells by positive selection
using Dynabeads (Invitrogen, Paisley, UK) as previously
described.5 Cells (1 9 106 cells/ml) were cultured in RPMI-
1640 containing 10% fetal calf serum, 2 mM L-glutamine
and 50 lg/ml gentamycin, and stimulated with plate-bound
anti-CD3 (1 lg/ml; OKT-3) plus 50 IU/ml recombinant
human IL-2 (Eurocetus, Harefield, UK), in the presence or
absence of 1,25(OH)2D3 (ENZO Life Sciences, Exeter, UK),
TGF-b and/or blocking anti-IL-10 receptor antibody (R&D
Systems, Abingdon, UK) at the indicated concentrations.
For Treg cell and effector T cell isolation, CD4+ cells were
isolated by negative selection using the Rosette CD4+
enrichment kit (StemCell Technologies, Grenoble, France)
from cones obtained from the National Blood Service. To
identify ‘Treg’ CD4+ T cells (CD25+ CD127lo) and ‘effector’
CD4+ T cells (CD25– CD127hi) isolation was performed
using a FACSAria Flow Cytometer (BD Biosciences, Oxford,
UK) and sort criteria were based on CD127 and CD25 sur-
face staining as described previously.5
Cell proliferation was studied by labelling populations
with CellTrace Violet (Invitrogen). Proliferation was
assessed as the loss of CellTraceTM Violet fluorescence on
day 7 and day 14 cell cultures using a FACSCanto (BD
Biosciences).
Flow cytometry
CD3, CD25 (SK7 and M-A251 respectively; BD Biosciences)
and CD127 (eBioRDR5; eBiosciences Hatfield, UK) anti-
bodies were used for cell surface phenotyping. Cells were
then further stained for intranuclear Foxp3 (PCH101; eBio-
sciences) using the Foxp3 staining kit as per the manufac-
turer’s instructions (eBiosciences).
For intracellular cytokine staining on day 7, cells were
restimulated for 4 hr with 5 ng/ml PMA and 500 ng/ml
ionomycin, with 2 lM monensin (Sigma-Aldrich, St
Louis, MO) added for the final 2 hr. Cells were washed,
fixed and permeabilized using Cytofix/Cytoperm kit (BD
Biosciences) and then stained with fluorescently labelled
monoclonal antibodies to IL-2 (MQ1-17H12; eBioscienc-
es). Dead cells (7-aminoactinomycin D-positive; Sigma-
Aldrich, Gillingham, UK) were gated out.
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For phospho-STAT5 staining two different buffer kits
were used with the same antibody clone: 47/Stat5[pY694]
obtained from BD Biosciences. The buffer set used for
phospho-STAT5 staining on total CD4+ cell populations
was PerFix EXPOSE Kit (Beckman Coulter, High
Wycombe, UK). The buffer set used for phopspho-STAT5
staining on sorted Treg cell and effector T cell popula-
tions was CytoFix/CytoPerm Buffer and Perm Buffer III
(BD Biosciences). Both buffer sets were used as per the
manufacturer’s instructions.
Quantitative RT-PCR
RNA was extracted from cell pellets using the RNeasy
Mini kit (Qiagen, Crawley, UK) according to the manu-
facturer’s instructions. The RNA was quantified using a
Nanodrop ND-1000 spectrophotometer (ThermoScientif-
ic, Wilmington, DE) then 250 ng of RNA was reverse
transcribed into cDNA. Quantitative RT-PCR was per-
formed in triplicate using an Applied Biosystems 7900 HT
system and FAM-labelled Assay-on-Demand reagent sets
for foxp3 (Hs00203958_m1) and il2 (Hs00174114_m1).
Quantitative RT-PCR were multiplexed using VIC-labelled
18S primers and probes (Hs99999901_s1) as an endoge-
nous control and analysed using SDS SOFTWARE version 2.1
(Applied Biosystems, Foster City, CA), according to the
2(ΔΔCt) method.
Flow cytometric and statistical analysis
Flow data obtained from BD FACSCalibur were analysed
using CELLQUEST PRO (BD Biosciences) while samples
acquired on a BD FACSCanto or BD LSR Fortessa were
analysed using FLOWJO (Treestar Inc., Ashland, OR). Data
analysis was performed in GRAPHPAD PRISM version 6.00
for Windows obtained from Graphpad Software Inc. (San
Diego, CA) using statistical tests detailed in the figure leg-
end.
Results
TGF-b increased the frequency of 1,25(OH)2D3
induced Foxp3+ Treg cells
We previously reported that human CD4+ T cells stimu-
lated with anti-CD3 (1 lg/ml) and IL-2 (50 IU/ml) in
the presence 107 M 1,25(OH)2D3 did not significantly
increase the frequency of Foxp3+ Treg cells in culture. In
the current study the addition of TGF-b was assessed in
combination with 1,25(OH)2D3, to determine whether it
could promote Foxp3+ Treg cell generation in vitro. The
addition of TGF-b into CD4+ T-cell cultures containing
107 M 1,25(OH)2D3 led to a reproducible and significant
increase in Foxp3+ CD25hi Treg cells after both 7 and
14 days of culture (Fig. 1a,b). This increase in Foxp3+
Treg cell populations was not due to differential cell
death (see Supporting information, Fig. S1A). Quantita-
tive RT-PCR analysis demonstrated a significant increase
in foxp3 gene expression in these conditions (Fig. 1c).
The combination of TGF-b and the blocking antibody to
IL-10 receptor was assessed based on our earlier findings,5
in the same experimental system. Although the combina-
tion of TGF-b and anti-IL-10 receptor significantly
increased the frequency of Foxp3+ Treg cells (see Sup-
porting information, Fig. S2), this increase was not signif-
icantly greater than the effects of TGF-b alone. Therefore
the rest of this study focused on the mechanisms through
which TGF-b, in combination with 107 M 1,25(OH)2D3,
promotes Foxp3+ Treg cell frequency.
TGF-b with 1,25(OH)2D3 lead to preferential
expansion of Foxp3+ Treg cells
To investigate the mechanism through which the combi-
nation of 107 M 1,25(OH)2D3 and TGF-b increases the
frequency of Foxp3+ Treg cells, proliferation was assessed
in CD4+ T-cell populations. Cells were labelled at day 0
with CellTraceTM and then proliferation was assessed by
loss of fluorescence after 7 days of culture. Foxp3 staining
was additionally performed to determine the impact of
these culture conditions on the proliferation of Treg
(Foxp3+) versus effector (Foxp3) CD4+ T cells (Fig. 2a).
Significantly more proliferation, expressed as per cent of
divided cells, was seen in the Foxp3+ compared with the
Foxp3 T-cell population in cultures containing 1,25
(OH)2D3 plus TGF-b, suggesting that these conditions
favour the expansion of Foxp3+ Treg cells (Fig. 2a,b). This
effect of 1,25(OH)2D3 and TGF-b on the proliferation of
effector T cells may explain why there was differential cell
recovery at day 7 (see Supporting information, Fig. S1B).
1,25(OH)2D3 plus TGF-b significantly increased IL-2
expression in CD4+ T cells
Since the addition of TGF-b induced preferential expansion
of Foxp3+ Treg cells in 1,25(OH)2D3-containing cultures,
how TGF-bmodulates Foxp3+ Treg cells in this experimen-
tal system was addressed next. Interleukin-2 is important
for induction, maintenance and proliferation of Foxp3+
Treg cells and the impact of TGF-b on IL-2 expression and
signalling was therefore investigated.13,22,26–28,34
Interleukin-2 production was assessed by intracellular
cytokine staining to determine whether the conditions
that increased the frequency of Foxp3+ Treg cells also
increased IL-2 production. Although the presence of
107 M 1,25(OH)2D3 in culture showed a trend to
decreased IL-2 in culture (Fig. 3a), TGF-b alone and in
combination with 107 M 1,25(OH)2D3 significantly
increased the frequency of IL-2+ CD4+ T cells compared
with 1,25(OH)2D3 alone (Fig. 3a,b). Furthermore, il2
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mRNA expression was significantly increased in cultures
containing 107 M 1,25(OH)2D3 and TGF-b compared
with the no-drug condition (Fig. 3c). Intracellular
co-staining of IL-2 and Foxp3 showed that there was little
to no co-expression of IL-2 and Foxp3 (Fig. 3d), suggest-
ing that IL-2 is being produced by Foxp3 effector T cells.
These data suggest that one potential mechanism
through which the combination of 1,25(OH)2D3 and
TGF-b enhance the expansion of Foxp3+ Treg cells is by
increasing the availability of IL-2 in culture.
Modulation of CD25 expression in cultures
containing 1,25(OH)2D3 and TGF-b
Expression of the high affinity IL-2 receptor a (IL-2Ra;
CD25), was next assessed on Foxp3+ and Foxp3 CD4+
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Figure 1. 1,25(OH)2D3 in the presence of transforming growth factor-b (TGF-b) increases the frequency of Foxp3
+ regulatory T cells. CD4+ T
cells stimulated with anti-CD3 and interleukin-2 (IL-2) for 7 or 14 days alone (No drugs; ) or additionally with 1,25(OH)2D3 (VitD3; 107 M)
and/or TGF-b (2 ng/ml). (a) Representative dot plots; (b) cumulative data of Foxp3+ expression in CD4+ cells at day 7 (left; n = 7) and day 14
(right; n = 5); (c) cumulative data of relative foxp3 gene expression as determined by quantitative RT-PCR in the presence or absence of TGF-b
(grey; n = 5).Values represent the percentage of gated live cells in each gate. (b) Assessed by repeated measures one-way analysis of variance with
Tukey’s multiple comparison test (c) assessed by repeated measures one-way analysis of variance with Freidman’s post-test. *P ≤ 005,
**P ≤ 001, ***P ≤ 0001.
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Figure 2. Increased proliferation in Foxp3+ population compared with the Foxp3 population in conditions that enhance Foxp3+ Treg cells.
CD4+ T cells stimulated for 7 days with anti-CD3 and interleukin-2 (IL-2) alone (No drugs; ) or additionally with 1,25(OH)2D3 (VitD3;
107 M) and/or transforming growth factor-b (TGFb; 2 ng/ml). Cells were labelled at day 0 with CellTraceTM and proliferation was assessed by
loss in fluorescence. (a) Representative histograms of CellTrace expression in Foxp3 (black; solid) and Foxp3+ (black; dotted) CD4+ T cells. (b)
Cumulative data of the percentage of original population divided in Foxp3 (white) and Foxp3+ (black) at day 7 (n = 5). (b) Assessed by paired
t-test. *P ≤ 005, **P ≤ 001.
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Figure 3. Increased interleukin-2 (IL-2) secretion in conditions that enhance the frequency of Foxp3+ regulatory T (Treg) cells. CD4+ T cells
stimulated for 7 days with anti-CD3 and IL-2 alone (No drugs; ) or additionally with 1,25(OH)2D3 (VitD3; 107 M) and/or transforming
growth factor-b (TGF-b; 2 ng/ml). Intracellular cytokine staining was performed following 4 hr of stimulation with PMA/ionomycin with
Monensin added for the final 2 hr. (a) Representative dot plots, (b) cumulative data of frequency of IL-2+ cells at day 7 (n = 5), (c) cumulative
data of relative il2 gene expression as determined by quantitative RT-PCR (n = 7), (d) representative dot plots of Foxp3 and IL-2 co-staining.
Values represent the percentage of gated live cells in each quadrant. (b) and (c) assessed by repeated measures one-way analysis of variance with
Freidman’s post-test.*P ≤ 005.
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T cells. Following culture of CD4+ T cells for 7 days with
anti-CD3 and IL-2 plus 107 M 1,25(OH)2D3 and TGF-b,
a significant increase in the expression of CD25 on
Foxp3+ Treg cells, but not on Foxp3 CD4+ T cells was
observed compared with cultures lacking 1,25(OH)2D3
and TGF-b (Fig. 4a,b). These data suggest that there is a
greater capacity for IL-2 consumption by Foxp3+ Treg
cells under these culture conditions.
To prove that IL-2 was being predominantly consumed
by Foxp3+ Treg cells in the presence of 107 M 1,25
(OH)2D3 and TGF-b, phosphorylation of STAT5 was
used as a marker of IL-2 signalling. Downstream of IL-2
ligation of CD25 there is phosphorylation of tyrosine at
site 694 (Y694), a prerequisite for STAT5 activation.35,36
When phosphorylation of STAT5 was assessed in total
CD4+ T-cell cultures no significant difference was
observed between the culture conditions (Fig. 5a,b). To
understand further which cells were using the IL-2 pro-
duced in the presence of 1,25(OH)2D3 and TGF-b the
consumption of IL-2 by Foxp3+ Treg cells was assessed.
As there is incompatibility between buffers, Foxp3 and
STAT5 staining could not be performed simultaneously.
Therefore Treg cells were sorted based on
CD127lo CD25hi expression, and effector T cells were
identified as being CD127hi CD25lo/–. Typically, 87% of
the Treg cells isolated were Foxp3+, whereas < 1% of the
effector T cells were Foxp3+ (see reference 5). The Treg
or effector T cells were labelled with CellTraceTM and co-
cultured at a regulator : effector ratio of 1 : 9 with anti-
CD3 and IL-2 in the presence or absence of 107 M 1,25
(OH)2D3 and/or TGF-b. At day 7 intracellular staining
for STAT5 phosphorylation was performed. In cultures
containing 1,25(OH)2D3 and TGF-b, phosphorylation of
STAT5 was considerably higher in Treg cells and lower in
effector T cells compared with the no drug and 1,25
(OH)2D3 conditions (Fig. 5c).
In conclusion, these data suggest that 107 M 1,25
(OH)2D3 and TGF-b collectively promote Foxp3
+ Treg
cells through increasing IL-2 secretion from CD4+ effector
T cells, which is then preferentially consumed by Foxp3+
Treg cells.
Discussion
The cytokine environment is recognized to play an
important role in the generation and maintenance of
Foxp3+ CD4+ T-cell populations. Evidence from epidemi-
ological studies, animal models and ex vivo data all sug-
gest a role for vitamin D in positively influencing the
frequency of CD4+ Foxp3+ Treg cells.4–7 Studies with
human T cells suggest that in vitro 1,25(OH)2D3 opti-
mally enhances the frequency of these cells only when
present at very high concentrations or under conditions
of strong T-cell stimulation.5,8 The data presented in this
paper propose that the cytokines IL-2 and TGF-b have
key co-operative functions in enhancing frequencies of
1,25(OH)2D3-induced Foxp3
+ Treg cells. These data
complement our earlier findings, which demonstrated
that the cytokine milieu, in particular IL-10, had a nega-
tive impact on the frequency of 1,25(OH)2D3-induced
Foxp3+ Treg cells and enhanced IL-10+ Treg cells.5
Historically, TGF-b has been shown to be important
for the induction of Foxp3+ Treg cells from naive CD4+
T cells, and IL-2 is proposed to be an essential compo-
nent in TGF-b-mediated induction of Foxp3+ Treg
cells.13,30,34 Additionally, TGF-b has the capacity to con-
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vert effector as well as naive CD4+ T cells into Foxp3+
Treg cells when in the presence of the vitamin A metabo-
lite retinoic acid.15–20 The current work builds on these
earlier findings and proposes that like retinoic acid, the
combination of TGF-b and 1,25(OH)2D3 significantly
increase the frequency of Foxp3+ Treg cells.
A proposed mechanism for the increase in Foxp3+
T cells in cultures containing TGF-b and 1,25(OH)2D3
was due to the preferential expansion of these cells com-
pared with the Foxp3 CD4+ T cells. This preferential
expansion of Foxp3+ Treg cells is believed to be due, at
least in part, to an increase in IL-2 production in culture
in the presence of TGF-b alone or in combination with
1,25(OH)2D3. Interleukin-2 has been shown to be vitally
important for the TGF-b-mediated increase in Foxp3+
Treg cells, and in the absence of IL-2 there was no
Foxp3+ Treg cell induction.13,30,34 As predicted, the
increased production of IL-2 in conditions containing
TGF-b originated from the effector T cells, which is in
agreement with previous reports describing that Foxp3+
Treg cells do not produce their own IL-2. Interestingly
unpublished data from our laboratory showed that in the
absence of Treg cells there was more proliferation in the
effector T cell cultures, again indicating that the Foxp3+
Treg cells were out-competing effector T cells in culture
for the growth factor IL-2. Furthermore, in the presence
of both 1,25(OH)2D3 and TGF-b there was enhanced
usage of IL-2, as evidenced by the increased phosphoryla-
tion of STAT5 in Foxp3+, compared with the Foxp3
T-cell population.
The study of human Foxp3+ Treg cell populations is
difficult because the immunological tools do not readily
exist to adequately distinguish between ‘natural’ Foxp3+
Treg cells, adaptive/induced Treg cell or even early activa-
tion-dependent Foxp3 expression. However evidence from
our earlier studies,5 where we observed that 1,25(OH)2D3
caused little to no inhibition of the proliferation of sorted
populations of Foxp3+ Treg cells (CD25hi CD127lo), but
significantly inhibited the proliferation of effector T cells
suggests that the observed effects are due to effects on
existing rather than de novo induced Treg cells. It also
seems unlikely that we are observing proliferation of acti-
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Figure 5. Interleukin-2 (IL-2) is preferentially consumed by Foxp3+ regulatory T (Treg) cells when transforming growth factor-b (TGF-b) and
1,25(OH)2D3 are present. Total CD4
+ T cells were cultured for 7 days with anti-CD3 and IL-2 (No drugs; ) or additionally with 1,25(OH)2D3
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vation-induced Foxp3+ cells because our culture condi-
tions (anti-CD3 and IL-2) do not provide a strong enough
stimulus. Furthermore, the cultures in this study have a
much longer duration whereas activation-induced Foxp3
expression is a rapid event which is then lost.37 Additional
evidence to support our data includes the strong positive
correlation observed in vivo between vitamin D sufficiency
and Foxp3+ Treg cell numbers and frequency.4,5,7
Early studies into the effects of 1,25(OH)2D3 and TGF-
b individually on IL-2 production from CD4+ T cells
have shown that they inhibit IL-2 production, which is in
contrast with the data presented here where we see an
enhancement of IL-2.38,39 In those studies, lower concen-
trations of 1,25(OH)2D3 were investigated, and the TGF-
b work was performed in mice, which may in part
explain the differences observed. Nevertheless, these data
do provide a potential mechanism by which Foxp3+ T
cells are increased in the presence of 1,25(OH)2D3
through enhanced availability of IL-2, an essential cyto-
kine for Treg cell function, and for maintenance, survival
and stability of Foxp3+ cells.12,13,22,23,34
Historically a central role in the generation of the
active form of vitamin D, 1,25(OH)2D3, was through
metabolism in the kidney from the circulating precursor
25(OH)D. However, subsequent work has shown that a
number of additional cell types have the capability of
generating 1,25(OH)2D3 from 25(OH)D, many of which
are found in the lung including monocytes, dendritic cells
and epithelial cells.40–43 Monocyte-derived DCs have been
reported to metabolize 1,25(OH)2D3 to concentrations of
1 9 109 M to 6 9 108 M in culture.42–44 Hence con-
centrations investigated in the current study appear to
approach physiologically relevant levels and probably rep-
resent concentrations potentially found in the lung. How-
ever, it is still technically challenging to address this issue
experimentally. Nonetheless it seems credible that concen-
trations of 1,25(OH)2D3 required to increase Treg cell
populations can be achieved locally in the tissues.
This work provides further evidence for an important
role of 1,25(OH)2D3 as an immunomodulatory molecule,
and illustrates that a wide range of concentrations of 1,25
(OH)2D3 have the capacity to promote Foxp3
+ Treg cells
depending on the cytokine milieu. The data suggest that
supplementation of vitamin-D-deficient individuals, who
are reported to have reduced numbers of circulating and
airway Foxp3+ Treg cells,4–7 may represent an attractive
therapy for enhancing endogenous populations of Treg
cells as seen in a recent study on subcutaneous allergen
immunotherapy.45 Administering vitamin D supplemen-
tation to increase endogenous Treg cell populations in
transplant recipients and autoimmune patients may also
be an option. In addition, vitamin D treatment might
provide a conditioning environment to enhance the sur-
vival and functionality of Foxp3+ Treg cells in strategies
involving adoptive transfer of Treg cells.
In summary, 1,25(OH)2D3 represents an attractive
approach for the treatment of chronic inflammatory dis-
eases such as asthma. Vitamin D supplementation may
offer a relatively safe, acceptable and cost-effective thera-
peutic option to promote peripheral tolerance and there-
fore warrants further investigation.
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